Dose escalation of biologics in Crohn’s disease: critical review of observational studies

References

• Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012;380:1590-605
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis 2010;4:28-62
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Date of issue of marketing authorization: 8.9.2003. Humira assessment report. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000481/human_med_000822.jsp&mid=WC0b01ac058001d124. Accessed January 16, 2017
   Google Scholar
• European Medicines Agency. Date of issue of marketing authorization: 13.8.1999. Remicade authorization details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000240/human_med_001023.jsp&mid=WC0b01ac058001d124. Accessed January 16, 2017
   Google Scholar
• European Medicines Agency. Report issued 20.3.2014. Entyvio assessment report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002782/WC500168530.pdf. Accessed January 16, 2017
   Google Scholar
• Schreiber S. Certolizumab pegol for the treatment of Crohn’s disease. Therap Adv Gastroenterol 2011;4:375-89
   PubMedGoogle Scholar
• Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol 2011;106:674-84
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097
   PubMed Web of Science ®Google Scholar
• Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003;73:712-6
   PubMed Web of Science ®Google Scholar
• Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patients. J Crohns Colitis 2013;7:154-60
   PubMed Web of Science ®Google Scholar
• Amiot A, Hulin A, Belhassan M, Andre C, et al. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. Clin Res Hepatol Gastroenterol 2016;40:90-98
   PubMed Web of Science ®Google Scholar
• Bhalme M, Sharma A, Keld R, et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease? Eur J Gastroenterol Hepatol 2013;25:543-9
   PubMed Web of Science ®Google Scholar
• Brandse JF, Peters CP, Gecse KB, et al. Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn’s disease. Inflamm Bowel Dis 2014;20:251-8
   PubMed Web of Science ®Google Scholar
• Chaparro M, Andreu M, Barreiro-de Acosta M, et al. Effectiveness of infliximab after adalimumab failure in Crohn’s disease. World J Gastroenterol 2012;18:5219-24
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lama Y, Roman ALS, Marin-Jimenez I, et al. Open-label infliximab therapy in Crohn’s disease: A long-term multicenter study of efficacy, safety and predictors of response. Gastroenterol Hepatol 2008;31:421-6
   PubMedGoogle Scholar
• Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s Disease. Gastroenterology 2009;137:1628-40
   PubMed Web of Science ®Google Scholar
• Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007;13:129-34
   PubMed Web of Science ®Google Scholar
• Russo EA, Iacucci M, Lindsay JO, et al. Survey on the use of adalimumab as maintenance therapy in Crohn’s disease in England and Ireland. Eur J Gastroenterol Hepatol 2010;22:334-9
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: Results from a single-centre cohort. Gut 2009;58:492-500
   PubMed Web of Science ®Google Scholar
• Sprakes MB, Ford AC, Warren L, et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn’s disease: A large single centre experience. J Crohns Colitis 2012;6:143-53
   PubMed Web of Science ®Google Scholar
• Eshuis EJ, Peters CP, van Bodegraven AA, et al. Ten years of infliximab for Crohn’s disease: Outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis 2013;19:1622-30
   PubMed Web of Science ®Google Scholar
• Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn’s perineal fistulas. Am J Gastroenterol 2009;104:2973-86
   PubMed Web of Science ®Google Scholar
• Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009;29:286-97
   PubMed Web of Science ®Google Scholar
• Molnar T, Farkas K, Nyari T, et al. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience. J Gastrointestin Liver Dis 2012;21:265-9
   PubMed Web of Science ®Google Scholar
• Riis A, Martinsen TC, Waldum HL, et al. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. Scand J Gastroenterol 2012;47:649-57
   PubMed Web of Science ®Google Scholar
• Reenaers C, Louis E, Belaiche J, et al. Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Aliment Pharmacol Ther 2012;36:1040-8
   PubMed Web of Science ®Google Scholar
• Castano-Milla C, Chaparro M, Saro C, et al. Effectiveness of adalimumab in perianal fistulas in Crohn’s disease patients naive to anti-TNF therapy. J Clin Gastroenterol 2015;49:34-40
   PubMed Web of Science ®Google Scholar
• Chaparro M, Panes J, Garcia V, et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose “Escalation” in patients losing response. J Clin Gastroenterol 2011;45:113-9
   PubMed Web of Science ®Google Scholar
• Chaparro M, Martinez-Montiel P, Van Domselaar M, et al. Intensification of infliximab therapy in Crohn’s disease: Efficacy and safety. J Crohns Colitis 2012;6:62-7
   PubMed Web of Science ®Google Scholar
• Filippi J, Agrefilo D, Fontas E, et al. Comparison of efficacy and tolerance of two maintenance regimens with adalimumab in patients with moderate to severe Crohn’s disease. J Crohns Colitis 2013;7:S235
   Google Scholar
• Mantzaris GJ, Kyriakos N, Papamichael K, et al. Factors influencing the time to and outcome of dose escalation of adalimumab in Crohn’s disease patients who achieved steroid-free remission on adalimumab. Presented at the 9th Congress of ECCO; Copenhagen, Denmark, February 20–22, 2014
   Google Scholar
• Nichita C, Stelle M, Vavricka S, et al. Clinical experience with adalimumab in a multicenter Swiss cohort of patients with crohn's disease. Digestion 2010;81:78-85
   PubMed Web of Science ®Google Scholar
• Oussalah A, Babouri A, Chevaux J-B, et al. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 2008;29:416-23
   PubMed Web of Science ®Google Scholar
• Pariente B, Pineton de Chambrun G, Krzysiek R, et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:1199-206
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Radivojevica S, Manserb CN, et al. Addressing current treatment challenges in Crohn’s disease in real life: A physician’s survey. Dig Liver Dis 2014;46:1066-71
   PubMedGoogle Scholar
• Lindsay JO, Chipperfield R, Giles A, et al. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther 2013;38:52-61
   PubMed Web of Science ®Google Scholar
• Bultman E, De Haar C, Van Liere-Baron A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients. Aliment Pharmacol Ther 2012;35:335-41
   PubMed Web of Science ®Google Scholar
• Kiss LS, Szamosi T, Molnar T, et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease. Aliment Pharmacol Ther 2011;34:911-22
   PubMed Web of Science ®Google Scholar
• Taxonera C, Olivares D, Mendoza JL, et al. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2014;20:9170-7
   PubMed Web of Science ®Google Scholar
• Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012;18:2026-33
   PubMed Web of Science ®Google Scholar
• Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011;33:349-57
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. First published 25.1.2008. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000624/smops/Negative/human_smop_000024.jsp&mid=WC0b01ac058001d127. Accessed February 23, 2017
   Google Scholar
• Chaparro M, Panes J, Garcia V, et al. Long-term durability of response to adalimumab in Crohn’s disease. Inflamm Bowel Dis 2012;18:685-90
   PubMed Web of Science ®Google Scholar
• Fortea-Ormaechea JI, Gonzalez-Lama Y, Casis B, et al. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn’s disease. The Madrid experience. Gastroenterol Hepatol 2011;34:443-8
   PubMed Web of Science ®Google Scholar
• Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 2014;109:1250-6
   PubMed Web of Science ®Google Scholar
• Bouguen G, Laharie D, Nancey S, et al. Efficacy and safety of adalimumab 80mg weekly in Crohn’s disease. J Crohns Colitis 2013;7:S219
   Google Scholar
• Magro F, Bastos R, Marques M, et al. Infliximab dose intensification by shortening infusion intervals. Inflamm Bowel Dis 2008;14:432-4
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis 2017;11:3-25
   PubMed Web of Science ®Google Scholar
• Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010;31:92-101
   PubMed Web of Science ®Google Scholar
• Gagniere C, Beaugerie L, Pariente B, et al. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn’s disease. J Crohns Colitis 2015;9:349-55
   PubMed Web of Science ®Google Scholar
• Fries W, Privitera AC, Belvedere A, et al. Long-term infliximab treatment in Crohn’s disease – Efficacy and safety. Presented at the 6th Congress of ECCO, Dublin, Ireland, February 24–26, 2011
   Google Scholar
• Hommes DW, van de Heisteeg BH, van der Spek M, et al. Infliximab treatment for Crohn’s disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis 2002;8:81-6
   PubMed Web of Science ®Google Scholar
• Budas SJ, Seenan JP, Jamieson N, et al. How often do we discontinue maintenance infliximab due to clinical remission in Crohn's disease? Presented at the 9th Congress of ECCO, Copenhagen, Denmark, February 14–16, 2014
   Google Scholar
• Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2015;13:522-30
   PubMed Web of Science ®Google Scholar
• Aguas M, Bastida G, Cerrillo E, et al. Adalimumab in prevention of postoperative recurrence of Crohn’s disease in high-risk patients. World J Gastroenterol 2012;18:4391-8
   PubMed Web of Science ®Google Scholar
• Archavlis E, Papamichael K, Tzivras D, et al. Adalimumab for patients with Crohn’s disease and secondary loss of response or severe allergy to infliximab. Abstract P177. Presented at the 6th Congress of the European Crohn’s and Colitis Organisation (ECCO), Dublin, Ireland, February 24–26, 2011. https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2011/item/197.html
   Google Scholar
• Bodini G, Savarino V, Dulbecco P, et al. Correlation between adalimumab trough serum concentration, anti-adalimumab antibodies and TNF-a levels with clinical outcome in patients affected by Crohnès disease. Abstract P295. United Eur Gastroenterol J 2013;1(1S):A211
   Google Scholar
• Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohns Colitis 2013;7:736-43
   PubMed Web of Science ®Google Scholar
• Carvalho D, Bernardes C, Russo P, et al. Adalimumab in perianal Crohn’s disease treatment: Experience of a tertiary center. Presented at the 10th Congress of ECCO, Barcelona, Spain, February 18–21, 2015
   Google Scholar
• Caviglia R, Ribolsi M, Rizzi M, et al. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007;13:5238-44
   PubMed Web of Science ®Google Scholar
• Echarri A, Ollero V, Barreiro-de Acosta M, et al. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease: predictors of efficacy in clinical practice. Eur J Gastroenterol Hepatol 2015;27:430-5
   PubMed Web of Science ®Google Scholar
• Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004–2008). Aliment Pharmacol Ther 2009;29:527-34
   PubMed Web of Science ®Google Scholar
• Ho GT, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohn’s disease. Aliment Pharmacol Ther 2008;27:308-15
   PubMed Web of Science ®Google Scholar
• Juillerat P, Sokol H, Froehlich F, et al. Factors associated with durable response to infliximab in Crohn’s disease 5 years and beyond: A multicenter international cohort. Inflamm Bowel Dis 2015;21:60-70
   PubMed Web of Science ®Google Scholar
• Lopez Palacios N, Mendoza JL, Taxonera C, et al. [Adalimumab induction and maintenance therapy for Crohn’s disease. An open-label study]. Rev Esp Enferm Dig 2008;100:676-81
   PubMed Web of Science ®Google Scholar
• Magro F, Rodrigues-Pinto E, Coelho R, et al. Is it possible to change phenotype progression in crohn’s disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol 2014;109:1026-36
   PubMed Web of Science ®Google Scholar
• Orlando A, Renna S, Mocciaro F, et al. Adalimumab in steroid-dependent Crohn’s disease patients: Prognostic factors for clinical benefit. Inflamm Bowel Dis 2012;18:826-31
   PubMed Web of Science ®Google Scholar
• Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn’s disease treated with combination therapy. Am J Gastroenterol 2010;105:1142-9
   PubMed Web of Science ®Google Scholar
• Papamichael K, Vande-Casteele N, Gils A, et al. Long-term outcome of patients with Crohn’s disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol 2015;13:1103-10
   PubMed Web of Science ®Google Scholar
• Peeters H, Louis E, Baert F, et al. Efficacy of switching to infliximab in Crohn’s disease patients with loss of response to adalimumab. Presented at the 9th Congress of ECCO; Copenhagen, Denmark, February 20–22, 2014
   Google Scholar
• Peters CP, Eshuis EJ, Toxopeus FM, et al. Adalimumab for Crohn’s disease: long-term sustained benefit in a population-based cohort of 438 patients. J Crohns Colitis 2014;8:866-75
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007;25:675-80
   PubMed Web of Science ®Google Scholar
• Sprakes MB, Hamlin PJ, Warren L, et al. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn’s disease: A single centre experience. J Crohns Colitis 2011;5:324-31
   PubMed Web of Science ®Google Scholar
• Tambasco R, Gionchetti P, Laureti S, et al. Adalimumab in the treatment of perianal Crohn’s disease: Long term results in a single tertiary center. Presented at the 7th Congress of ECCO; Barcelona, Spain, February 16–18, 2012
   Google Scholar
• Viazis N, Koukouratos T, Anastasiou J, et al. Azathioprine discontinuation earlier than 6 months in Crohn’s disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. Eur J Gastroenterol Hepatol 2015;27:436-41
   PubMed Web of Science ®Google Scholar
• West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther 2008;28:1122-6
   PubMed Web of Science ®Google Scholar
• Magro F, Rodrigues-Pinto E, Santos-Antunes J, et al. High C-reactive protein in Crohn’s disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis 2014;8:129-36
   PubMed Web of Science ®Google Scholar